id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2000-N-0143-0007,FDA,FDA-2000-N-0143,Answer from FDA CDER to Honorable Rosa L. DeLauro,Other,Answer,2015-03-13T04:00:00Z,2015,3,2015-03-13T04:00:00Z,,2024-12-04T04:46:45Z,,0,0,09000064804d0de7
FDA-2000-N-0143-0002,FDA,FDA-2000-N-0143,"Applications for Food and Drug Administration Application Approval to Market a New Drug; Revision of
Postmarketing Reporting Requirements",Notice,Notice of Final Rule,2007-10-19T04:00:00Z,2007,10,2007-10-18T04:00:00Z,,2025-06-13T00:26:00Z,E7-20510,0,0,09000064804d0dec
FDA-2000-N-0143-0001,FDA,FDA-2000-N-0143,"Applications for FDA Approval to Market a New Drug; Proposed Revision of Postmarketing Reporting
Requirements",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2000-11-08T05:00:00Z,2000,11,2000-11-07T05:00:00Z,2001-02-06T04:59:59Z,2025-06-13T00:25:01Z,00-28519,0,0,09000064804d0dc5